GeneDx Holdings Corp. (WGS)
NASDAQ: WGS · IEX Real-Time Price · USD
27.28
+0.24 (0.89%)
At close: Jun 12, 2024, 4:00 PM
25.40
-1.88 (-6.89%)
After-hours: Jun 12, 2024, 7:28 PM EDT
Company Description
GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services.
The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.
It provides genetic diagnostic tests, screening solutions, and information with a focus on pediatrics, rare diseases for children and adults, and hereditary cancer screening.
GeneDx Holdings Corp. was founded in 2017 and is headquartered in Stamford, Connecticut.
GeneDx Holdings Corp.
| Country | United States |
| Founded | 2017 |
| Industry | Health Information Services |
| Sector | Healthcare |
| Employees | 1,000 |
| CEO | Ms. Katherine A. Stueland |
Contact Details
Address: 333 Ludlow Street, North Tower, 8th Floor Stamford, Connecticut 06902 United States | |
| Phone | 617 780 8742 |
| Website | genedx.com |
Stock Details
| Ticker Symbol | WGS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001818331 |
| CUSIP Number | 81663L200 |
| ISIN Number | US81663L2007 |
| Employer ID | 85-1966622 |
| SIC Code | 8000 |
Key Executives
| Name | Position |
|---|---|
| Katherine A. Stueland | President, Chief Executive Officer and Director |
| Kevin Feeley | Chief Financial Officer |
| Karen Ponchner | Senior Vice President and Head of Operations |
| Eric Olivares Ph.D. | Chief Product and Technology Officer |
| Devin K. Schaffer J.D., M.B.A. | General Counsel |
| Paul Kruszka M.D. | Chief Medical Officer |
| Melanie Duquette | Chief Growth Officer |
| Sabrina Dunbar | Chief of Staff |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 31, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Apr 30, 2024 | 424B5 | Filing |
| Apr 29, 2024 | 8-K | Current Report |
| Apr 29, 2024 | 424B5 | Filing |
| Apr 29, 2024 | ARS | Filing |
| Apr 29, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 29, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 29, 2024 | 10-Q | Quarterly Report |
| Apr 29, 2024 | 8-K | Current Report |
| Feb 26, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |